Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia

Summary

This study is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR positive for the PML-RARα transcript or rarer retinoid sensitive subtypes (i.e. NPM-RAR-alpha, NuMA-RARalpha) and less than 21 years of age (for AIEOP, see appendix A).

Timeline

Start

2009-01

Primary completion

2017-06

Completion

2018-12

Drugs

Indications